Full year revenue and EBITDA in line with guidance
Accelerating product development post-COVID-19 to become a leading global clinical diagnostic company in infectious diseases
Paris, France and Eastleigh, UK 27 April 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its audited results for the year ended 31 December 2022.
Full year 2022 results
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Novacyt SA published this content on 27 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2023 06:17:07 UTC.